Does Bimzelx Hurt During Injection?
Bimzelx (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor for plaque psoriasis, hidradenitis suppurativa, and psoriatic arthritis, is given as a subcutaneous injection. Injection-site reactions occur in 12-20% of patients, including pain, redness, itching, or swelling.[1][2] These are usually mild to moderate and resolve within days. Patients often describe a brief stinging or burning sensation at the injection site, similar to other biologics like Stelara or Cosentyx, but less severe than some TNF inhibitors.
How Patients Describe the Pain
Real-world reports note the needle (27-gauge, 1/2-inch) feels sharp but quick—most say it hurts less than expected, rating it 2-4/10 on pain scales.[3] Pre-filled syringes or auto-injectors minimize discomfort; rotating sites (abdomen, thigh, upper arm) helps. Cold application or room-temperature storage reduces sting. Some users on forums like Drugs.com report no pain after the first few doses as they adapt technique.
What Side Effects Beyond Injection Pain?
Common side effects include upper respiratory infections (15-20%), oral candidiasis (7-14%, due to IL-17 blockade), and fatigue.[1][2] Serious risks like infections or hypersensitivity occur in <1%, with no widespread reports of chronic pain from the drug itself. Long-term data (up to 3 years) show injection pain decreases over time.[4]
Tips to Make Injections Less Painful
- Let it reach room temperature (30 minutes out of fridge).
- Use ice pack 5-10 minutes before.
- Inject slowly after pinching skin; don't rub after.
- If pain persists >1 week or worsens, consult a doctor—could signal reaction.
How Does Bimzelx Compare to Other Biologics for Pain?
Bimzelx has fewer injection-site reactions than secukinumab (Cosentyx, 20-25%) but similar to ixekizumab (Taltz).2 Infusion-based options like Remicade avoid needles entirely but require clinic visits.
[1]: Bimzelx Prescribing Information, UCB Pharma (FDA label, 2023).
[2]: ClinicalTrials.gov, NCT04908723 (BE VIVID trial).
[3]: Drugs.com user reviews (aggregated 2024).
[4]: Journal of the American Academy of Dermatology (3-year safety data, 2023).